<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01232881</url>
  </required_header>
  <id_info>
    <org_study_id>HOG COE-03</org_study_id>
    <nct_id>NCT01232881</nct_id>
  </id_info>
  <brief_title>Predicting Response and Toxicity in Patients Receiving Lonafarnib for Breast Cancer</brief_title>
  <official_title>Predicting Response and Toxicity in Patients Receiving Lonafarnib for Breast Cancer: A Multicenter Genomic, Proteomic and Pharmacogenomic Correlative Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoosier Cancer Research Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Indiana University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hoosier Cancer Research Network</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a tumor and serum collection study for patients with advanced breast cancer receiving
      treatment with lonafarnib.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OUTLINE: This is a multi-center study.

      Sample Collection:

        -  Tumor sample

        -  Serum sample

      Treatment Regimen:

        -  All registered patients must be planning treatment with lonafarnib
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    funding terminated
  </why_stopped>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To correlate tumor gene expression (genomic profile) with response to lonafarnib in patients with advanced breast cancer</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To correlate serum and tumor proteomic profiles with response to lonafarnib</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare serum and tissue proteomic analyses</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare genomic and proteomic profiles</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To correlate toxicity and /or response with drug-specific pharmacogenomic parameters</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">27</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Tumor and Serum Collection</arm_group_label>
    <description>Tumor sample submission can consist of a fresh frozen tissue sample or a formalin-fixed paraffin embedded tissue block.
Serum is to be collected prior to the initiation of lonafarnib treatment and 28 days after the last dose of lonafarnib.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Tumor Sample</intervention_name>
    <description>Tumor sample submission can consist of a fresh frozen tissue sample or a formalin-fixed paraffin embedded tissue block.</description>
    <arm_group_label>Tumor and Serum Collection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Serum Sample</intervention_name>
    <description>Serum is to be collected prior to the initiation of lonafarnib treatment and 28 days after the last dose of lonafarnib.</description>
    <arm_group_label>Tumor and Serum Collection</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Tumor sample submission can consist of a fresh frozen tissue sample or a formalin-fixed
      paraffin embedded tissue block.

      Serum is to be collected prior to the initiation of lonafarnib treatment and 28 days after
      the last dose of lonafarnib.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will be limited to patients with advanced breast cancer receiving
        treatment with lonafarnib.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent and HIPAA authorization for release of personal health
             information. NOTE: HIPAA authorization may be included in the informed consent or
             obtained separately.

          -  Age &gt; 18 years.

          -  Planned treatment with lonafarnib for metastatic breast cancer.

          -  Must consent to have a biopsy performed to obtain fresh tissue or be able to identify
             a formalin fixed paraffin embedded (FFPE) tissue block in which tumor samples can be
             obtained to complete the testing for this study.

        Exclusion Criteria:

          -  Planned treatment with any other treatment regimen
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George Sledge, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Hoosier Cancer Research Network</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Indiana University Melvin and Bren Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.hoosieroncologygroup.org</url>
    <description>Hoosier Oncology Group Homepage</description>
  </link>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 2010</study_first_submitted>
  <study_first_submitted_qc>November 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2010</study_first_posted>
  <last_update_submitted>April 27, 2011</last_update_submitted>
  <last_update_submitted_qc>April 27, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 28, 2011</last_update_posted>
  <responsible_party>
    <name_title>George Sledge, M.D.</name_title>
    <organization>Hoosier Oncology Group</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lonafarnib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

